Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for ...
2009 NOV 23 ... applications of RNAi, technology advances in other areas of drug discovery, such as biologics manufacturing, exemplify the broad transformative potential of RNAi." ALN-TTR Program ...
2009 NOV 23 ... BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced that it has ...
2009 NOV 23 ... pipeline, and leverage our company's experience in developing and delivering novel biologics to help patients prevail over rheumatoid arthritis and, potentially, other autoimmune ...
2009 NOV 23 ... and scleroderma, chronic kidney disease/glomerulosclerosis. Most of the molecules are biologics (antibodies, proteins, peptides, antisense, vaccine, cells). The most advanced projects ...
2009 NOV 23 ... history, including approximately 60 unique potential medicines--both small molecules and biologics--in human testing. Additionally, Steve has helped to recruit many of the top leaders we ...
2009 NOV 23 ... a response to the FDA's Complete Response letter regarding the review of Dyax's Biologics License Application (BLA) of DX-88 for the treatment of hereditary angioedema (HAE). The ...
2009 NOV 23 ... place significant downward pressures on prices; reviewing the length of exclusivity for biologics and entry for biosimilars, which could tilt the balance of generic and patented market ...
2009 NOV 23 ... technology is garnering for its ability to be chemically linked to small molecules and biologics such as siRNA and peptide therapeutics to transform existing and experimental ...
2009 NOV 23 ... efforts in fighting HIV/AIDS in the developing world and the development of a generic biologics strategy contributed to the decision to grant Mylan SA this honor. The ...
2009 NOV 23 ... so improving solubility can have a tremendous impact on NCE's, reformulations, and even biologics. Whatever the case, Enavail's proprietary particle design technologies provide ...
2009 NOV 23 ... in our future success. Our goal at Osteotech is to continue to commercialize proprietary biologics designed to address the unmet needs of the surgeon community and we believe these ...
2009 NOV 24 ... in this growing therapeutic area. Earlier this year, PPD significantly expanded its biologics and vaccines testing capabilities when it acquired a vaccine testing lab in Wayne, ...
2009 NOV 23 ... and colleagues published their study in the Journal of Cutaneous Medicine and Surgery (Biologics in the Treatment of Psoriasis: Clinical and Economic Overview. Journal of Cutaneous ...
2009 NOV 23 ... Dr. Thompson has been actively involved in over 200 clinical trials for drugs, biologics and devices, and has been associated with numerous FDA regulatory submissions. She ...
2009 NOV 23 ... and a potential increase in the total percentage of patients who receive treatment with biologics," stated Amanda Puffer, analyst at Decision Resources. By combining ...
2009 NOV 16 ... (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON=AE (pegylated interferon alfa-2b) for the ...
2009 NOV 16 ... Carlos Barbas of The Scripps Institute, is very compelling due to its ability to create biologics that are single protein-combination therapeutics in a manner that is likely to be ...
